Taxol as Second-Line Treatment in Patients with Advanced Ovarian Cancer after Platinum-Based First-Line Chemotherapy

By Mayerhofer K.   Kucera E.   Zeisler H.   Speiser P.   Reinthaller A.   Sevelda P.  

Gynecologic Oncology, Vol. 64, Iss. 1, 1997-01 ,pp. : 109-113

Elsevier

Access to resources Recommend Favorite

Utility of Gene Promoter Methylation in Prediction of Response to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC)

By Chaudhry Parvesh   Srinivasan Radhika   Patel Firuza  

Cancer Investigation, Vol. 27, Iss. 8, 2009-10 ,pp. : 877-884

Informa Healthcare

Access to resources Recommend Favorite

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

By Wilop Stefan   Hobe Sabine   Crysandt Martina   Esser Albert   Osieka Rainhardt   Jost Edgar  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 10, 2009-10 ,pp. : 1429-1435

Springer Publishing Company

Access to resources Recommend Favorite

Chemotherapy with Doxorubicin, Etoposide and Cyclophosphamide (DEC) in Ovarian Cancer Persistent after Platinum-based Treatment

By Zanetta G.   Monico S.L.   Gabriele A.   Miceli D.   Mangioni C.  

European Journal of Cancer, Vol. 32, Iss. 1, 1996-01 ,pp. : 178-179

Elsevier

Access to resources Recommend Favorite

Response to Salvage Treatment in Recurrent Ovarian Cancer Treated Initially with Paclitaxel and Platinum-Based Combination Regimens

By Roland P.Y.   Barnes M.N.   Niwas S.   Robertson M.W.   Alvarez R.   Austin J.M.   Kilgore L.C.   Partridge E.E.  

Gynecologic Oncology, Vol. 68, Iss. 2, 1998-02 ,pp. : 178-182

Elsevier

Access to resources Recommend Favorite